Literature DB >> 9645719

Identification of glaucoma-related visual field abnormality with the screening protocol of frequency doubling technology.

H A Quigley1.   

Abstract

PURPOSE: To evaluate the predictive power of frequency doubling technology to distinguish glaucoma suspects from persons with glaucoma visual field loss.
METHODS: A consecutive series of 76 subjects referred to a glaucoma service underwent perimetry in one eye with frequency doubling technology in a screening mode and Humphrey 24-2 threshold testing in random order, and had optic disk and clinical nerve fiber layer grading.
RESULTS: All subjects performed perimetry with both instruments satisfactorily, with an average test time of 1.8 +/- 0.7 minutes per eye for the frequency doubling technology (instrument time). Of 33 eyes classified as abnormal by glaucoma hemifield test, 91% (30/33) were abnormal on frequency doubling technology (two or more abnormal locations of 17), whereas 94% (31/33) of glaucoma suspects with normal Humphrey fields had normal results with frequency doubling technology. Frequency doubling technology results were highly correlated with Humphrey mean deviation by linear regression (r2 = .74, P = .047) and with corrected pattern standard deviation probability value. A frequency doubling technology error score for each quadrant of the field was highly correlated with the number of severely abnormal points per quadrant in Humphrey threshold tests (r2 = .63, P = .034). There was close agreement between clinical examination of the optic disk and nerve fiber layer and frequency doubling technology results. Three-level quantification of abnormality in frequency doubling technology results did not add to diagnostic accuracy.
CONCLUSION: Frequency doubling technology testing shows promise as a screening method in glaucoma.

Entities:  

Mesh:

Year:  1998        PMID: 9645719     DOI: 10.1016/s0002-9394(98)00046-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  39 in total

1.  Retinal ganglion cell death in experimental glaucoma.

Authors:  J E Morgan; H Uchida; J Caprioli
Journal:  Br J Ophthalmol       Date:  2000-03       Impact factor: 4.638

2.  Clinical comparison of frequency doubling technology perimetry and Humphrey perimetry.

Authors:  R Casson; B James; A Rubinstein; H Ali
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

3.  Psychophysical characterisation of early functional loss in glaucoma and ocular hypertension.

Authors:  E A Ansari; J E Morgan; R J Snowden
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

4.  The distribution of visual field defects per quadrant in standard automated perimetry as compared to frequency doubling technology perimetry.

Authors:  Wadih M Zein; Ziad F Bashshur; Rola F Jaafar; Baha' N Noureddin
Journal:  Int Ophthalmol       Date:  2010-10-06       Impact factor: 2.031

5.  Performance of the 24-2-5 frequency doubling technology screening test: a prospective case study.

Authors:  P G D Spry; H M Hussin; J M Sparrow
Journal:  Br J Ophthalmol       Date:  2007-03-27       Impact factor: 4.638

Review 6.  [Functional glaucoma diagnosis].

Authors:  C Erb; K Göbel
Journal:  Ophthalmologe       Date:  2009-04       Impact factor: 1.059

Review 7.  Effect of cataract extraction on frequency doubling technology perimetry in patients with glaucoma.

Authors:  M A R Siddiqui; A Azuara-Blanco; S Neville
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

8.  Anatomic and functional correlation of frequency-doubling technology perimetry (FDTP) in multiple sclerosis.

Authors:  Harold Merle; Stéphane Olindo; Angélique Donnio; Raymond Richer; Didier Smadja; Philippe Cabre
Journal:  Int Ophthalmol       Date:  2011-06-03       Impact factor: 2.031

9.  Population and high-risk group screening for glaucoma: the Los Angeles Latino Eye Study.

Authors:  Brian A Francis; Rohit Varma; Cheryl Vigen; Mei-Ying Lai; Jonathan Winarko; Betsy Nguyen; Stanley Azen
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-05       Impact factor: 4.799

10.  Visual evoked potential and psychophysical contrast thresholds in glaucoma.

Authors:  Siti Nurliyana Abdullah; Gordon F Sanderson; Andrew C James; Ted Maddess
Journal:  Doc Ophthalmol       Date:  2014-03-11       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.